Geron inks $935m Janssen deal after clinical hold lift

Geron will get $35m up front and may earn up to $900m in milestone fees plus royalties on future sales of the telomerase inhibitor imetelstat under the biotechnology company's worldwide license and collaboration agreement with Johnson & Johnson's Janssen Biotech subsidiary.